Firas Al-Rshoud

Firas Al-Rshoud

Auto-generated profile, based on publicly available information

Firas Al-Rshoud

Department of Obstetrics and Gynecology, Faculty of Medicine, The Hashemite University, Zarqa 13133, Jordan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Reproductive BioMedicine Online
Verified
Journal Article
Closed access
HHHoda Maaly Harb
Hoda Maaly Harb
JGJayasish Ghosh
Jayasish Ghosh
FAFiras Al-Rshoud
Firas Al-Rshoud
BKBala Karunakaran
Bala Karunakaran
IGIoannis D Gallos
Ioannis D Gallos
ACArri Coomarasamy
Arri Coomarasamy

1 January 2022 in JBRA Assisted Reproduction
Verified
Journal Article
Open access
SASoha Albeitawi
Soha Albeitawi
JHJehan Hamadneh
Jehan Hamadneh
FRFiras Al Reshoud
Firas Al Reshoud
EMEhab Abu Marar
Ehab Abu Marar
RHRami Hamzah
Rami Hamzah
PVPaola Viagano
Paola Viagano
During in vitro fertilization (IVF) cycles, final oocyte maturation is usually triggered by human Chorionic Gonadotropin (hCG) for its known effect in mimicking Luteinizing Hormone (LH) surge; however, with the widespread use of the ‘antagonist protocol’, Gonadotropin Releasing Hormone agonist (GnRHa) is being more commonly employed as a trigger in order to minimize or eliminate the risk of ovarian hyper-stimulation syndrome (OHSS). Many studies proved its efficacy in inducing oocyte maturation and its safety in preventing OHSS in high-risk groups. Moreover, some studies showed that GnRHa trigger may improve oocyte yield. This study aimed to further explore any beneficial effect of adding GnRHa to hCG (dual trigger) on oocyte yield and fertilization rate in normal responder women. We retrospectively reviewed and analyzed the data from 127 patients on antagonist protocol (67 dual trigger and 60 HCG trigger). The number of total oocytes, the number of MII oocytes and the number of fertilized oocytes were all significantly higher with the dual trigger protocol compared to hCG-only trigger. However, there is no significant difference in clinical pregnancy rate. Using the dual trigger improved the number and quality of oocytes, and the fertilization rate in normal responders.

31 March 2021 in Current Obstetrics and Gynecology Reports
Verified
Journal Article
Closed access
PDF file
FAFiras Al-Rshoud
Firas Al-Rshoud
AQAzmi Qudsi
Azmi Qudsi
FNFiras Wael Naffa
Firas Wael Naffa
BOBayan Al Omari
Bayan Al Omari
AAAreen Ghazi AlFalah
Areen Ghazi AlFalah

1 January 2021 in Journal of Human Reproductive Sciences
Verified
Journal Article
Open access
PDF file
FRFiras Al Rshoud
Firas Al Rshoud
RKRami Kilani
Rami Kilani
FAFida Al Asali
Fida Al Asali
OAOmar Assi
Omar Assi
NINedaa Ikhlaif
Nedaa Ikhlaif
WMWard Maaita
Ward Maaita
Aim: This study aims to evaluate the effect of endometrial polyp resection by office hysteroscopy during in vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) treatment cycle on pregnancy rate. Setting and Design: A retrospective observational study (case series). Materials and Methods: Twenty-five patients from a total of 346 patients that started IVF/ICSI treatment due to different causes of infertility over the period from January 2018 to December 2019 underwent an office hysteroscopy during ovarian stimulation (day 7–8) due to suspected endometrial polyp by transvaginal ultrasound and confirmed at day 7 of ovarian stimulation were retrospectively investigated. Results: Eighteen patients from the 25 patients that started IVF/ICSI treatment; endometrial polyp was confirmed by office hysteroscopy and resected, egg collection performed after 4–5 days after the hysteroscopy, embryo transfer done Double ET) at Day 3 and 5, the clinical Pregnancy rate was 56% (10 from the 18). No hysteroscopy-related adverse events were reported. Conclusion: Office hysteroscopy during ovarian stimulation in the IVF/ICSI treatment cycle may be useful in confirming the diagnosis and resection of endometrial polyp suspected by transvaginal ultrasound and is safe on the endometrium in terms of receptivity and improvement of the pregnancy rate. As the sample size of our study is relatively small, a well-designed large RCT is required to confirm our results before clinical advice is released.

27 June 2022 in Journal of Turkish Society of Obstetric and Gynecology
Verified
Journal Article
Open access
EAEbraheem Albazee
Ebraheem Albazee
LALina Almahmoud
Lina Almahmoud
FAFiras Al-Rshoud
Firas Al-Rshoud
DSDima Sallam
Dima Sallam
WAWardah Albzea
Wardah Albzea
AAAhmed Abu-Zaid
Ahmed Abu-Zaid
This investigation examined the efficacy of ondansetron (intervention) versus metoclopramide (control) in managing parturient females with hyperemesis gravidarum (HG), by pooling data from randomized controlled trials (RCTs) using a meta-analysis approach. From inception until January 2022, five information sources were screened: Cochrane Central Register of Controlled Trials, Google Scholar, Scopus, PubMed and Web of Science. Quality assessment was done through the Cochrane Risk of Bias (version 2) assessment tool. The mean difference (MD) with 95% confidence interval (CI) was used to summarize the continuous data in a fixed- or random-effects model, depending on the extent of between-study heterogeneity. Five RCTs were included, comprising a total of 695 patients (355 and 340 females were assigned to ondansetron and metoclopramide, respectively). Four RCTs had an overall ???low??? risk of bias, whereas one RCT had an overall ???some concerns??? due to lack of sufficient information about randomization. There was no significant difference between both groups regarding the pregnancy-unique quantification of emesis and nausea score [MD=0.23, 95% CI (-0.42, 0.88), p=0.49], length of hospital stay [MD=-0.17 days, 95% CI (-0.35, 0.02), p=0.08], the number of doses of drug received [MD=0.45, 95% CI (-0.08, 0.98), p=0.10], and duration of intravenous fluids [MD=-1.73 hours, 95% CI (-5.79, 2.33), p=0.40]. Among parturient females with HG, there was no substantial difference in efficacy between both agents. Nevertheless, ondansetron is favored over metoclopramide in view of its trending therapeutic efficacy and better safety profile.

1 January 2021
Verified
Journal Article
Closed access
FAFiras M. Al-Rshoud
Firas M. Al-Rshoud
HAHaya Mohammed Abujledan
Haya Mohammed Abujledan
NANusaibah Tawfik Alsanabani
Nusaibah Tawfik Alsanabani
AQAzmi Qudsi
Azmi Qudsi
AKAbdulmalik Koya
Abdulmalik Koya
HHHashim Talib Hashim
Hashim Talib Hashim
Yemen is one of the poorest countries in the world. It suffers from a genuine crisis in all areas, the most important of which is the health sector. Yemen has been suffering from conflicts for the last six years, and a high percentage of the population is dependent on international aid. After the worldwide spread of the SARS-CoV-2 virus, the virus that causes Coronavirus Disease 2019 (COVID-19), the first laboratory-confirmed case was announced in Yemen on April 10, 2020. Since then, as of 22 December 2020, 2,091 confirmed cases and 607 deaths have been reported. These numbers are not trustworthy because many cases are hidden by Houthi rebels (14). Citizens took the necessary precautions out of fear of infection, such as imposing quarantines, closing airports, and restricting public gatherings (1,8,14). Quarantines are only imposed in some cities in the southern part of the country, while the part controlled by Houthi rebels is not well organized in terms of imposing quarantines, and schools were opened due to the lack of technical devices and internet for online education.